Orthopaedic Department Waldkliniken Eisenberg, Orthopaedic Professorship of the University Hospital Jena, Klosterlausnitzer Str. 81, 07607, Eisenberg, Germany.
Sci Rep. 2020 Aug 3;10(1):13053. doi: 10.1038/s41598-020-69958-0.
Locally applied vancomycin is increasingly being used in primary hip and knee arthroplasty to reduce the risk of infection. Despite encouraging initial results, considerable debate remains on the basis of the data currently available. In particular, it has been unclear up to now whether local vancomycin is suitable to further reduce the risk of infection even if the rate of infection is already low (< 1%). In this monocentric retrospective cohort study, all primary total hip and knee arthroplasties performed between 2013 and 2018 were included. After a change in procedure at the hospital, 1 g vancomycin powder was applied intraarticularly before wound closure. The remaining perioperative procedure was constant over the investigation period. The follow-up was one year. The presence of an infection according to the currently valid MSIS criteria was defined as the endpoint. In patients with TKA two infections (0.3%) were observed under vancomycin prophylaxis in contrast to 44 infections (1.3%) in the control group (p = 0.033). In patients with THA two infections (0.5%) were observed under vancomycin prophylaxis and 48 infections (1.1%) in the control group without local vancomycin but this difference was statistically not significant. No wound complications requiring revision were observed as a result of the vancomycin. On the basis of the results of this study, intraarticular application of vancomycin powder in total hip and knee arthroplasty may be considered. Prospective randomized studies have to confirm this promising results prior a common recommendation.Level of Evidence III Retrospective cohort study.
局部应用万古霉素在初次髋关节和膝关节置换术中越来越多地被用于降低感染风险。尽管初始结果令人鼓舞,但基于现有数据仍存在相当大的争议。特别是,到目前为止,还不清楚局部万古霉素是否适合进一步降低感染风险,即使感染率已经很低(<1%)。在这项单中心回顾性队列研究中,纳入了 2013 年至 2018 年间进行的所有初次全髋关节和膝关节置换术。在医院手术流程改变后,在关闭伤口前在关节内应用 1 克万古霉素粉末。在整个研究期间,剩余的围手术期流程保持不变。随访时间为一年。根据现行的 MSIS 标准,将感染的存在定义为终点。在 TKA 患者中,万古霉素预防组观察到 2 例(0.3%)感染,而对照组观察到 44 例(1.3%)感染(p=0.033)。在 THA 患者中,万古霉素预防组观察到 2 例(0.5%)感染,对照组未局部应用万古霉素,但观察到 48 例(1.1%)感染,但这一差异无统计学意义。万古霉素未导致任何需要翻修的伤口并发症。基于这项研究的结果,在全髋关节和膝关节置换术中关节内应用万古霉素粉末可以被考虑。需要前瞻性随机研究来证实这一有前途的结果,然后才能提出普遍建议。证据等级 III 回顾性队列研究。